Assessment of Fibrosis After Treatment with Direct-Acting Antiviral Drugs with or without Silymarin in Patients with Chronic Hepatitis C Related Liver Disease

Liver Fibrosis Assessment in Cases of Chronic Hepatitis C after Direct Acting Antivirals Therapy using Aspartate Aminotransferase to Platelet Ratio Index and Transient Elastograph

Assessment of Changes in Liver Fibrosis and Stiffness, Lipid Profile and Insulin Resistance in Patients with Chronic Hepatitis C Viral Infection Who Received Direct Acting Antivi

Non-invasive Evaluation of Liver Fibrosis Changes in Patients with Chronic ‎Hepatitis C after Directly Acting Antiviral Drugs

ASSESSMENT OF LIVER FIBROSIS BEFORE AND AFTER DIRECT ACTING ANTIVIRAL THERAPY IN COMPENSATED HCV RELATED LIVER DISEASE

Evaluating the effect of direct-acting agents on liver fibrosis, by real-time elastography, Fibroscan and FIB4 score in chronic HCV patients

Assessment of Incidence of Hepatocellular Carcinoma among Hepatitis C Patients Who Achieved Sustained Virological Response with Direct Acting Antiviral Agents (DAAs)

Impact of Direct Acting Antivirals Therapy on Novel Fibrosis Index for Assessment of Hepatic Fibrosis in Comparison with AST to Platelet Ratio and Fibrosis-4 (FIB-4) Indexes in E

A Study of Hepatocellular Carcinoma in Chronic Hepatitis C Patients Received Direct Acting Antiviral Drugs

A Novel Noninvasive Index for Assessment of Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis C Virus Infection